News 2024

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody –  drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial …